147 related articles for article (PubMed ID: 23501442)
1. A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir.
D'Avolio A; De Nicolò A; Agnesod D; Simiele M; Mohamed Abdi A; Dilly Penchala S; Boglione L; Cariti G; Di Perri G
J Pharm Biomed Anal; 2013 May; 78-79():217-23. PubMed ID: 23501442
[TBL] [Abstract][Full Text] [Related]
2. UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells.
De Nicolò A; Abdi AM; Boglione L; Baiett L; Allegra S; Di Perri G; D'Avolio A
J Pharm Biomed Anal; 2015 Nov; 115():443-9. PubMed ID: 26291788
[TBL] [Abstract][Full Text] [Related]
3. Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS.
Farnik H; El-Duweik J; Welsch C; Sarrazin C; Lötsch J; Zeuzem S; Geisslinger G; Schmidt H
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Dec; 877(31):4001-6. PubMed ID: 19864192
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients.
Agnesod D; De Nicolò A; Simiele M; Mohamed Abdi A; Boglione L; Di Perri G; D'Avolio A
J Pharm Biomed Anal; 2014 Mar; 90():119-26. PubMed ID: 24366212
[TBL] [Abstract][Full Text] [Related]
5. Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer.
Penchala SD; Tjia J; El Sherif O; Back DJ; Khoo SH; Else LJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Aug; 932():100-10. PubMed ID: 23831525
[TBL] [Abstract][Full Text] [Related]
6. Determination of telaprevir in plasma of HCV-infected patients by HPLC-UV.
Tempestilli M; Milano E; D'Offizi G; Montalbano M; D'Avolio A; Gasperi T; Narciso P; Ascenzi P; Pucillo LP
IUBMB Life; 2013 Sep; 65(9):800-5. PubMed ID: 23893913
[TBL] [Abstract][Full Text] [Related]
7. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.
Susser S; Welsch C; Wang Y; Zettler M; Domingues FS; Karey U; Hughes E; Ralston R; Tong X; Herrmann E; Zeuzem S; Sarrazin C
Hepatology; 2009 Dec; 50(6):1709-18. PubMed ID: 19787809
[TBL] [Abstract][Full Text] [Related]
8. UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients.
Notari S; Tempestilli M; Fabbri G; Libertone R; Antinori A; Ammassari A; Agrati C
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():183-190. PubMed ID: 29276983
[TBL] [Abstract][Full Text] [Related]
9. Validation of a sensitive LC/MS/MS method for the determination of telaprevir and its R-isomer in human plasma.
Chen X; Bushman LR; McAllister KJ; Anderson PL; Kiser JJ
Biomed Chromatogr; 2014 Dec; 28(12):1714-21. PubMed ID: 24760592
[TBL] [Abstract][Full Text] [Related]
10. HCV RNA viral load assessments in the era of direct-acting antivirals.
Cobb B; Pockros PJ; Vilchez RA; Vierling JM
Am J Gastroenterol; 2013 Apr; 108(4):471-5. PubMed ID: 23552304
[TBL] [Abstract][Full Text] [Related]
11. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.
Susser S; Vermehren J; Forestier N; Welker MW; Grigorian N; Füller C; Perner D; Zeuzem S; Sarrazin C
J Clin Virol; 2011 Dec; 52(4):321-7. PubMed ID: 21924672
[TBL] [Abstract][Full Text] [Related]
12. Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.
Klibanov OM; Vickery SB; Olin JL; Smith LS; Williams SH
Pharmacotherapy; 2012 Feb; 32(2):173-90. PubMed ID: 22392426
[TBL] [Abstract][Full Text] [Related]
13. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
[TBL] [Abstract][Full Text] [Related]
14. Future of hepatitis C therapy: development of direct-acting antivirals.
Dore GJ; Matthews GV; Rockstroh J
Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
[TBL] [Abstract][Full Text] [Related]
15. Trends in hepatitis C virus infection therapy: protease inhibitors a step forward in the era of direct acting antivirals.
Popescu C; Gliga S; Aramă V
Rom J Intern Med; 2012; 50(2):117-27. PubMed ID: 23326955
[TBL] [Abstract][Full Text] [Related]
16. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
Butt AA; Kanwal F
Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
[TBL] [Abstract][Full Text] [Related]
17. UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients.
De Nicolò A; Simiele M; Pensi D; Boglione L; Allegra S; Di Perri G; D'Avolio A
J Pharm Biomed Anal; 2015 Oct; 114():127-32. PubMed ID: 26037161
[TBL] [Abstract][Full Text] [Related]
18. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
Marks KM; Jacobson IM
Antivir Ther; 2012; 17(6 Pt B):1119-31. PubMed ID: 23188750
[TBL] [Abstract][Full Text] [Related]
19. Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.
Aouri M; Moradpour D; Cavassini M; Mercier T; Buclin T; Csajka C; Telenti A; Rauch A; Decosterd LA
Antimicrob Agents Chemother; 2013 Jul; 57(7):3147-58. PubMed ID: 23629707
[TBL] [Abstract][Full Text] [Related]
20. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
Seden K; Back D
Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
